- €76.80m
- €42.44m
- €54.30m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.83 | ||
| Price to Tang. Book | 0.9 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 1.47 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -10.92% | ||
| Return on Equity | -4.12% | ||
| Operating Margin | -21.57% | ||
Financial Summary
| Year End 31st Dec | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | €m | 110.89 | 210.34 | 18.17 | 25.29 | 54.3 | n/a | n/a | -16.35% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | +154.34 | -92.92 | +587.13 | -91.38 | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Novogenia AG, formerly Darwin AG, is a Germany-based company, which operates as a biotechnology company. The Company is engaged in production and distribution of personalized dietary supplements and cosmetics. It offers Deoxyribonucleic Acid (DNA), genetic and blood analyses in the lifestyle segment. In addition, test results are primarily used to produce dietary supplements and cosmetics. The Company is active in Pharmaceutical and medical device trading segment as well. It uses artificial intelligence (AI) to create personalized solutions from scientific laboratory analysis data (personalized infusion therapies and In Vitro Fertilization (IVF)/reproductive genetics).
Directors
- Last Annual
- December 31st, 2025
- Last Interim
- June 30th, 2026
- Incorporated
- March 18th, 2021
- Public Since
- November 2nd, 2021
- No. of Employees
- 204
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
XETRA- Shares in Issue
- 12,000,000
- Address
- Brienner Strasse 7, MUNICH, 80333
- Web
- https://novogenia.com
- Phone
- +49 8920500450
- Auditors
- Treuhandgesellschaft Sudbayern GmbH Wirtschaftsprufungsgesel
Upcoming Events for 7V0
Similar to 7V0
FAQ
As of Today at 04:25 UTC, shares in Novogenia AG are trading at €6.40. This share price information is delayed by 15 minutes.
Shares in Novogenia AG last closed at €6.40 and the price had moved by -4.48% over the past 365 days. In terms of relative price strength the Novogenia AG share price has underperformed the FTSE Global All Cap Index by -16.32% over the past year.
There is no consensus recommendation for this security.
Find out moreThe Novogenia AG dividend yield is 8.75% based on the trailing twelve month period.
Last year, Novogenia AG paid a total dividend of €0.56, and it currently has a trailing dividend yield of 8.75%. We do not have any data on when Novogenia AG is to next pay dividends.
We do not have data on when Novogenia AG is to next pay dividends. The historic dividend yield on Novogenia AG shares is currently 8.75%.
To buy shares in Novogenia AG you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of €6.40, shares in Novogenia AG had a market capitalisation of €76.80m.
Here are the trading details for Novogenia AG:
- Country of listing: Germany
- Exchange: GER
- Ticker Symbol: 7V0
Based on an overall assessment of its quality, value and momentum Novogenia AG is currently classified as a Value Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Novogenia AG. Over the past six months, its share price has underperformed the FTSE Global All Cap Index by -30.04%.
As of the last closing price of €6.40, shares in Novogenia AG were trading -16.38% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Novogenia AG PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at €6.40.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on Novogenia AG's directors